HIV and Hepatitis C: CTN 260 Raltegravir Switch Study

March 2012

A randomized prospective open-label study of switching to raltegravir based antiretroviral therapy (ART) compared to maintaining ritonavir boosted protease inhibitor-based ART on liver fibrosis progression in HIV-HCV co-infected individuals.

Click the link below for more information and a short video on CTN 260